reports
- Jacob Mekhael
- Thomas Vranken
Sequana Medical FDA approval for alfapump
Sequana receives a nice Christmas present this year as it obtained PMA approval from the FDA for its alfapump system in the treatment of r/r ascites due to liver cirrhosis, ahead of the guided 1Q25 timeline. We see the approval as an important derisking event for the company, which will enable the company to address a market opportunity of $ >2bn (mgmt. estimates) in the US. The commercialisation intends to specifically target 90 liver transplant centres and is expected to launch in 2H25. We not...
- Hilde Van Boxstael
- Thomas Vranken
- Wim Lewi
Inventiva to present at the 43rd Annual J.P. Morgan Healthcare Confere...
Inventiva to present at the 43rd Annual J.P. Morgan Healthcare Conference Daix (France), New York City (New York, United States), December 17, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced that Frédéric Cren, CEO and cofounder of Inventiva, has been invited to prese...
Inventiva annonce sa participation à la « 43rd Annual J.P. Morgan Heal...
Inventiva annonce sa participation à la « 43rd Annual J.P. Morgan Healthcare Conference » Daix (France), New York City (New York, Etats Unis), le 17 décembre 2024 – Inventiva (Euronext Paris and Nasdaq :IVA) (la « Société »), société biopharmaceutique spécialisée dans le développement clinique de petites molécules administrées par voie orale pour le traitement des patients atteints de stéatohépatite associée à un dysfonctionnement métabolique (« MASH »), également connue sous le nom de stéatohépatite non alcoolique (« NASH »), et d’autres maladies avec un besoin médical non satisfait, annon...
Inventiva secures €21.4 million and completes the first tranche of the...
Inventiva secures €21.4 million and completes the first tranche of the previously announced multi-tranche financing of up to €348 million Inventiva secures €21.4 million leading to completion of the first tranche of the financing for c. €116 million, part of the multi-tranche equity financing of up to €348 million announced on October 14, 2024. Proceeds from the completed first tranche to be primarily used to advance Inventiva’s Phase III, NATiV3 clinical trial evaluating lanifibranor in patients with MASH. Appointment of Mark Pruzanski as new Chairman of the Board...
Inventiva obtient 21,4 millions d'euros complétant la première tranche...
Inventiva obtient 21,4 millions d'euros complétant la première tranche du financement multi-tranches annoncé précédemment d'un montant maximum de 348 millions d'euros Inventiva lève un montant de 21,4 millions d'euros permettant de compléter l’émission de la première tranche d’environ 116 millions d'euros du financement en fonds propres multi-tranches d'un montant maximum de 348 millions d'euros, annoncé le 14 octobre 2024. Le produit issu de cette première tranche finalisée du financement sera principalement utilisé pour faire progresser l'essai clinique de phase III, NATiV3, éva...
- Ahmed Ben Salem
- Emira Sagaama
- Oddo Sustainability Team
- Ahmed Ben Salem
- ING Helpdesk
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Lynn Hautekeete
- Wim Lewi
- Thijs Berkelder
- Wim Lewi
Elia Group New CEO confirmed and permanent CFO replacement announced
Earlier this week, press speculation emerged that Chairman Bernard Gustin would take the CEO position. Now it also emerges that interim CEO Catherine Vandenborre will not return to the CFO position, but instead leaves the group for a new career path on 30/6/25. Interim-CFO Marco Nix, who was already 10 years CFO of 50Hz will become full-time CFO on 1/4/25. While we regret that a seasoned manager leaves the company, there is now finally a solution for the executive management that will have to ex...
Results of the votes of the Combined Shareholders’ General Meeting of ...
Results of the votes of the Combined Shareholders’ General Meeting of December 11, 2024 Daix (France), New York City (New York, United States), December 11, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced the results of the votes of its Combined Shareholders’ Meeting....
Résultats des votes de l’Assemblée Générale Mixte des actionnaires – 1...
Résultats des votes de l’Assemblée Générale Mixte des actionnaires – 11 décembre 2024 Daix (France), New York City (New York, Etats-Unis), le 11 décembre 2024 – Inventiva (Euronext Paris et Nasdaq : IVA) (la « Société »), société biopharmaceutique spécialisée dans le développement clinique de petites molécules administrées par voie orale pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH »), également connue sous le nom de stéatohépatite non alcoolique (« NASH ») et d’autres maladies avec un besoin médical non satisfait significatif, annonce les résu...
- Guy Sips
- Jacob Mekhael
- Kristof Samoy
- Lynn Hautekeete
- Wim Lewi
- Nadège Tillier
European Utilities in 2025/And our picks and pans
We are bearish for the whole IG € corporate asset class in 2025. Utilities actively participle to this view. With an expected large issuance of €75bn, we believe that € Utilities will struggle to perform. The European utilities sector remains a healthy sector but, after an exceptional 2022/2023 period, the trend is decelerating. For some players, cash flow generation will suffer from lower power prices. We will continue to see growing capex and for network utilities more pressure on credit metri...
- Ahmed Ben Salem
- Christophe-Raphaël Ganet
- Thijs Berkelder
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Lynn Hautekeete
- Michiel Declercq
- Sharad Kumar S.P
- Wim Lewi
- Bruno Cavalier
- Chaima Ferrandon
- Charlotte Vaisse
- Sven Edelfelt
- Thomas Zlowodzki
DG VINCI SA
MT ARCELORMITTAL SA
CA CARREFOUR SA
MC LVMH MOET HENNESSY LOUIS VUITTON SE
FGR EIFFAGE SA
UHR SWATCH GROUP LTD. BEARER
RMS HERMES INTERNATIONAL SCA
EL ESSILORLUXOTTICA SA
BRBY BURBERRY GROUP PLC
KER KERING SA
VOW3 VOLKSWAGEN AG PREF
UCB UCB S.A.
01913 PRADA S.P.A.
ELI ELIA GROUP SA/NV
MONC MONCLER SPA
BC BRUNELLO CUCINELLI S.P.A.
CFR COMPAGNIE FINANCIERE RICHEMONT SA
STLA STELLANTIS N.V.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.